Registered Nurse Outpatient Oncology

Oncology Institute Data Breach 2026: third-party vendor compromise exposes patient data in kroll-administered systems. Executive summary. On May 20, 2026, The Oncology Institute, Inc. was notified by Kroll, the third-party administrator for its software vendor, of unauthorized access by a third party to certain company information systems, including those affecting patient data. This notification was formally disclosed in a U.S. Securities and Exchange Commission (SEC) Form 8-K filing on May 22, 2026. The incident was initially referenced in a prior 8-K filing on November 6, 2025, but at that time, there was no confirmation of patient data compromise. The May 2026 notification confirmed that systems affecting patient data were accessed, though the exact types of data compromised and the number of affected individuals remain unverified as of the latest public disclosures. The company's technology security and continuity plan allowed operations to continue without material disruption, and credit monitoring is being offered to impacted patients. The incident is part of a broader trend of third-party vendor breaches in the healthcare sector, which now represent a significant portion of all reported breaches. No specific threat actor, malware, or technical indicators have been publicly attributed to this incident, and the investigation is ongoing. All information in this summary is based on official SEC filings and sector technical analysis as of May 25, 2026. Technical information. The breach at The Oncology Institute was the result of a third-party vendor compromise, as confirmed by the official SEC Form 8-K filing and independent sector analysis (StockTitan SEC Filing, May 22, 2026; The CyberSignal, May 25, 2026). This attack vector is consistent with the MITRE ATT&CK Initial Access techniques, specifically Supply Chain Compromise (T1195) and Trusted Relationship (T1199). In a supply chain compromise, adversaries manipulate products or delivery mechanisms prior to receipt by the final consumer to gain unauthorized access (MITRE ATT&CK T1195). The trusted relationship technique involves exploiting the trust between an organization and its third-party vendors to access networks or data (MITRE ATT&CK T1199). The confidence level for this vector is high, as it is corroborated by primary and secondary sources. No specific malware, ransomware, or tools have been publicly disclosed in relation to this incident. There are no technical indicators such as file hashes, command-and-control infrastructure, or malware family names available in the public domain as of May 25, 2026. No threat actor or group has been attributed to the breach, and there is no evidence of ransomware deployment, data extortion, or data being offered for sale. The breach is part of a broader trend in the healthcare sector, where third-party vendor risk has become the dominant breach vector. According to the Verizon Data Breach Investigations Report (DBIR) 2026, third parties are involved in approximately 48% of healthcare breaches, representing a 60% increase year over year (The CyberSignal, May 25, 2026). Similar incidents in the sector have involved exposure of sensitive data such as names, Social Security numbers, medical records, and financial information, but for The Oncology Institute, the specific data types compromised remain unverified. The company's response included the activation of its technology security and continuity plan, which allowed operations to continue in all material respects. Credit monitoring and protection services are being offered to impacted patients. The company is also reserving its rights regarding potential claims against third parties or service providers. There is no evidence of operational disruption, ransomware, or data extortion as a result of this incident. The evidence hierarchy for this incident is as follows: there are no disclosed technical artifacts such as malware or indicators of compromise; the breach vector is strongly aligned with sector-wide third-party vendor compromise trends in healthcare (high confidence for vector, low confidence for actor attribution); and regulatory filings and sector reporting confirm the breach vector but do not provide technical attribution. Affected versions & timeline. The affected systems are those managed by a third-party software vendor and administered by Kroll on behalf of The Oncology Institute. The specific software versions or platforms involved have not been disclosed in public filings or sector reports. The timeline of the incident is as follows: the initial voluntary disclosure occurred in an SEC Form 8-K on November 6, 2025, without confirmation of patient data compromise. On May 20, 2026, the company was notified by Kroll of unauthorized access to systems affecting patient data. The formal SEC disclosure was filed on May 22, 2026. As of this filing, the investigation is ongoing, and the company has stated that the incident has not had a material impact on operations, financial systems, financial condition, or quality of care. Threat activity. The confirmed threat activity is unauthorized access to information systems affecting patient data, mediated through a third-party vendor. There is no public evidence of specific threat actor attribution, malware deployment, or data exfiltration for sale or fraud. The attack method is consistent with supply chain compromise and exploitation of trusted relationships, as defined in the MITRE ATT&CK framework. The incident is representative of a broader pattern in the healthcare sector, where adversaries increasingly target third-party vendors to gain access to sensitive data. No ransomware, extortion, or operational disruption has been reported in connection with this incident. The company's response has included offering credit monitoring to affected patients and reserving legal rights regarding third-party claims. Mitigation & workarounds. The following mitigation and workaround measures are recommended, prioritized by severity: Critical: Healthcare organizations should immediately inventory all third-party vendors with access to sensitive data and ensure that contractual and technical controls are in place to monitor and restrict such access. This includes reviewing and updating third-party risk management (TPRM) policies, conducting regular security assessments of vendors, and requiring timely breach notification clauses in all vendor contracts. High: Organizations should implement continuous monitoring of third-party data repositories, including the use of security information and event management (SIEM) tools to detect anomalous access patterns. Incident response plans should be updated to include scenarios involving third-party vendor breaches, and tabletop exercises should be conducted to test these plans. Medium: Ensure that all patient data stored or processed by third-party vendors is encrypted both at rest and in transit. Regularly review access logs and audit trails for signs of unauthorized access, and require vendors to provide evidence of their own security controls and certifications. Low: Provide ongoing security awareness training for staff, emphasizing the risks associated with third-party vendors and the importance of reporting suspicious activity. Maintain up-to-date documentation of all vendor relationships and data flows. The Oncology Institute's response - activation of continuity plans, offering of credit monitoring, and legal reservations - aligns with sector best practices for HIPAA-covered entities. Organizations should also monitor for regulatory updates and potential legal actions related to third-party breaches. About rescana. Rescana provides a third-party risk management (TPRM) platform designed to help organizations identify, assess, and monitor risks associated with external vendors and service providers. Its platform enables continuous visibility into vendor security posture, supports automated risk assessments, and facilitates incident response coordination for vendor-related breaches. For questions or further information, please contact Rescana Ltd. at [email protected].

The Oncology Institute has appointed Minh Merchant as Chief Legal Officer. She will oversee legal, regulatory, compliance and privacy functions as the value-based oncology group continues to scale. Merchant brings over 20 years of experience advising public and private healthcare organisations. She previously served as general counsel at Midi Health, Kyverna Therapeutics, Aspira Women's Health and McKesson, and holds a JD from UCLA School of Law. Founded in 2007, The Oncology Institute operates over 100 clinics across five US states, serving approximately 1.9 million patients. The company employs over 180 clinicians and provides cancer care including clinical trials and transfusions in community settings.